Barclays Maintains Overweight on Insmed, Lowers Price Target to $207
Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.
Share
Why It Matters
A bank analyst still likes Insmed but thinks it is worth less money. Watch if the company can prove it deserves a higher price again.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.